Background: The ablation of paroxysmal atrial fibrillation (PAF) by cryoballoon has increased dramatically in recent years. However, there are few data comparing first- and second-generation cryoballoons.
Aim: To compare safety and mid-term (2-year) efficacy of first- and second-generation cryoballoons in PAF ablation, using cryoballoon size tailored to pulmonary vein anatomy.
Methods: In this single-centre study, we included the last 50 consecutive PAF patients who underwent cryoballoon-based pulmonary vein isolation using the first-generation cryoballoon (CB-1) and the first 50 patients using the second-generation cryoballoon (CB-2). The choice of 23 or 28mm cryoballoon was driven by patient anatomy. After discharge, follow-up was with systematic outpatient visits at 3, 6, 9, 12 and 24 months, including 12-lead electrocardiogram, Holter monitoring and telephone interviews, plus additional electrocardiograms, as required, in case of symptoms. Arrhythmia recurrence was defined as a documented atrial tachycardia or fibrillation episode>30seconds after a 3-month blanking period.
Results: At 24 months, freedom from arrhythmia after a single procedure was similar for both generations of cryoballoon (72.0% and 72.0% for CB-1 and CB-2, respectively; P=0.95). Mean procedure and fluoroscopy times were longer in the CB-1 group than in the CB-2 group: 139±37.8 vs 95.2±21.3minutes and 10.2±7.2 vs 5.1±2.4minutes, respectively (P<0.02 for both). Transient right phrenic nerve palsy occurred only in the CB-1 group (five patients, 9.8%).
Conclusions: CB-1 and CB-2 showed similar efficacy for PAF ablation, with similar arrhythmia recurrence 24 months after a single ablation procedure. However, our findings suggest that CB-2 may have more effective cooling capabilities, enabling shorter procedure and fluoroscopy times.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.acvd.2017.01.015 | DOI Listing |
Obes Sci Pract
February 2025
Found Health, Inc. Austin Texas USA.
Background: Virtually-delivered obesity care has the potential to increase access to weight loss interventions at scale. While there is ample literature assessing various weight loss interventions, studies specifically demonstrating outcomes of commercial programs offering antiobesity medications in virtual care settings are lacking.
Methods: This retrospective cohort study assessed the weight loss outcomes of 66,094 participants in a virtual weight care program that prescribes antiobesity medications alongside a digital behavior change program.
Radiat Oncol
January 2025
Department of Oncology, The Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Yuzhong District, Chongqing, 400010, China.
Background: Patients with non-small cell lung cancer (NSCLC) are prone to developing brain metastases (BMs), particularly those with epidermal growth factor receptor (EGFR) mutations. In clinical practice, treatment-naïve EGFR-mutant NSCLC patients with asymptomatic BMs tend to choose EGFR-tyrosine kinase inhibitors (TKIs) as first-line therapy and defer intracranial radiotherapy (RT). However, the effectiveness of upfront intracranial RT remains unclear.
View Article and Find Full Text PDFDrug Metab Pharmacokinet
November 2024
Clinical Research, Drug Development Division, Sumitomo Pharma Co., Ltd., 33-94, Enoki-cho, Suita, Osaka, 564-0053, Japan. Electronic address:
The second-generation antipsychotic blonanserin is a highly selective, full antagonist of dopamine D and D and serotonin 5-HT receptors. It is currently prescribed for patients with schizophrenia in Japan. We aimed to develop a population pharmacokinetic model of oral blonanserin, including data from 12 to 77 years old patients, to assess the covariates that influence blonanserin pharmacokinetics and evaluate appropriate dosage regimens in adolescents versus adults.
View Article and Find Full Text PDFHist Philos Life Sci
January 2025
University of Buenos Aires, Buenos Aires, Argentina.
The goal of this paper is to explore a set of epistemological and ontological issues regarding the historical and philosophical role of placebos in the contested history of antidepressants. Starting from an account of the dual nature of the placebo as both an epistemic and a therapeutic tool, and against the background of the heated debates on the efficacy of second-generation antidepressants, I propose two related arguments. First, I argue that placebos as controls played a crucial but paradoxical role in the rise of so-called evidence-based approaches to depression.
View Article and Find Full Text PDFCatal Sci Technol
December 2024
Department of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern Freiestrasse 3 3012 Bern Switzerland
Even though α-arylation of ketones is attractive for direct C-H functionalization of organic substrates, the method largely relies on phosphine-ligated palladium complexes. Only recently, efforts have focused on developing nitrogen-based ligands as a more sustainable alternative to phosphines, with pyridine-functionalized pyridinium amidate (pyr-PYA) ,'-bidentate ligands displaying good selectivity and activity. Here, we report on a second generation set of catalyst precursors that feature a 5-membered N-heterocycle instead of a pyridine as chelating unit of the PYA ligand to provide less steric congestion for the rate-limiting transmetalation of the enolate.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!